CAR-EXPRESSING T Cells and CAR Expression Vector

EPO published patent EP3845654A1 on March 25, 2026, covering CAR-expressing T cells and CAR expression vectors developed by Noile-Immune Biotech and Takeda Pharmaceutical. The invention, with inventors Take, Chihiro, Tamiya, Takayuki, and Yamaguchi, Akiko, pertains to cellular immunotherapy compositions with applications in cancer treatment (A61P 35/00, A61P 35/02). The patent designates all major European contracting states including DE, FR, GB, IT, ES, NL, BE, CH, SE, and 25 others.\n\nThis is a routine patent publication conferring exclusive rights to the named applicants. No immediate compliance obligations arise for other parties. Competitors developing similar CAR T cell technologies should conduct freedom-to-operate analyses and consider whether licensing may be necessary. No regulatory deadlines or penalties are associated with this publication.